Gilead shares early clinical data on HIV capsid inhibitor 

Gilead began enrolling the first of a planned 32 HIV patients in a phase 1b in December. (Gilead China)

Gilead has posted early data on a first-in-class inhibitor of HIV-1 capsid function it thinks could play a role in long-acting combination therapies. The data supported the progress of the asset, GS-6207, into a phase 1b trial in HIV-1 infected adults. 

Teams at Gilead, Pfizer and other research groups have spent years looking into the capsid that cloaks the genetic material of HIV. As the capsid is vital to the virus and the RNA that encodes for it is fairly stable, disrupting the shell could deliver a critical blow to HIV without running the risk that resistance will quickly emerge. 

Gilead is now set to test that idea in the clinic. The advance of GS-6207 into patients was supported by data from healthy volunteers Gilead presented this week at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI).

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

The 40-subject study gave single, subcutaneous doses of GS-6207 of up to 450 mg. Having gathered 20 weeks of data on the 30 mg cohort and four weeks on the 450 mg arm, Gilead is yet to see any grade 3 or above adverse events. Most adverse events were mild and resolved. 

Gilead also has enough data from the two lower-dose cohorts to estimate the pharmacokinetic parameters of GS-6207. That has backed up Gilead’s belief that factors such as low human clearance will make GS-6207 suitable for use in extended-release formulations. The current data suggests a dosing interval of three months or more is possible.

With a favorable dosing schedule and characteristics that decrease the risk of resistance, GS-6207 could form part of a successful long-acting combination therapy. But Gilead is still some ways from generating the data to validate that hypothesis.

Gilead shared more in vitro data on GS-6207 at CROI, but the bigger efficacy tests are just getting started. Gilead began enrolling the first of a planned 32 HIV patients in a phase 1b in December and disclosed the activation of more sites this week. The study is looking at the maximum reduction in plasma HIV-1 RNA over the 10 days after they receive GS-6207. 


Suggested Articles

Biotronik received FDA approvals for six high-voltage cardiac rhythm management devices for treating and resynchronizing tachycardia and arrhythmias.

IRhythm’s ECG patch was able to improve atrial fibrillation diagnoses and lower numbers of ER visits by shifting patients to outpatient settings.

Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.